IT1145308B
(it)
*
|
1979-08-16 |
1986-11-05 |
Wellcome Found |
Composti aromatici sostituiti
|
GB8328757D0
(en)
*
|
1983-10-27 |
1983-11-30 |
Wellcome Found |
Chemical compounds
|
DE3600891A1
(de)
*
|
1986-01-15 |
1987-07-16 |
Bayer Ag |
1,8-verbrueckte 4-chinolon-3-carbonsaeuren und diese enthaltende arzneimittel
|
GB8613183D0
(en)
*
|
1986-05-30 |
1986-07-02 |
Wellcome Found |
Triazine salt
|
US4972496A
(en)
*
|
1986-07-25 |
1990-11-20 |
Grid Systems Corporation |
Handwritten keyboardless entry computer system
|
FI895821A0
(fi)
|
1988-12-07 |
1989-12-05 |
Wellcome Found |
Farmaceutiskt aktiva cns foereningar.
|
US5136080A
(en)
*
|
1989-12-04 |
1992-08-04 |
Burroughs Wellcome Co. |
Nitrile compounds
|
GB9012311D0
(en)
*
|
1990-06-01 |
1990-07-18 |
Wellcome Found |
Pharmacologically active cns compounds
|
GB9012312D0
(en)
*
|
1990-06-01 |
1990-07-18 |
Wellcome Found |
Pharmacologically active cns compounds
|
SK282071B6
(sk)
*
|
1991-01-30 |
2001-10-08 |
The Wellcome Foundation Limited |
Tableta dispergovateľná vo vode a spôsob jej prípravy
|
GB9124807D0
(en)
*
|
1991-11-22 |
1992-01-15 |
Wellcome Found |
Pharmaceutical formulations
|
US5629016A
(en)
*
|
1991-01-30 |
1997-05-13 |
Glaxo Wellcome Inc. |
Water-dispersible tablets
|
GB9203483D0
(en)
*
|
1992-02-19 |
1992-04-08 |
Wellcome Found |
Anti-inflammatory compounds
|
IL105986A
(en)
*
|
1992-06-12 |
1998-12-06 |
Wellcome Found |
Pharmaceutical preparations containing triazine compounds for the prevention or reduction of tolerable dependence or the opposite of dependency
|
GB9215908D0
(en)
*
|
1992-07-27 |
1992-09-09 |
Wellcome Found |
Water dispersible tablets
|
FR2699077B1
(fr)
*
|
1992-12-16 |
1995-01-13 |
Rhone Poulenc Rorer Sa |
Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
|
US6133299A
(en)
*
|
1993-02-25 |
2000-10-17 |
Warner-Lambert Company |
Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
|
GB9305693D0
(en)
*
|
1993-03-19 |
1993-05-05 |
Wellcome Found |
Therapeutic triazine compounds and use
|
US5866597A
(en)
*
|
1993-03-19 |
1999-02-02 |
Glaxo Wellcome Inc. |
Use of triazine compounds for the treatment of memory and learning disorders
|
GB9305692D0
(en)
*
|
1993-03-19 |
1993-05-05 |
Wellcome Found |
Therapeutic triazine compounds and use
|
US5698226A
(en)
*
|
1993-07-13 |
1997-12-16 |
Glaxo Wellcome Inc. |
Water-dispersible tablets
|
GB9317146D0
(en)
*
|
1993-08-18 |
1993-10-06 |
Wellcome Found |
Therapeutic combinations
|
GB9424766D0
(en)
*
|
1994-12-07 |
1995-02-08 |
Wellcome Found |
Pharmaceutical composition
|
GB9426448D0
(en)
*
|
1994-12-30 |
1995-03-01 |
Wellcome Found |
Process
|
US5912345A
(en)
*
|
1994-12-30 |
1999-06-15 |
Glaxo Wellcome Inc. |
Process for the preparation of lamotrigine
|
GB9512854D0
(en)
*
|
1995-06-23 |
1995-08-23 |
Wellcome Found |
Novel formulation
|
GB9518027D0
(en)
*
|
1995-09-05 |
1995-11-08 |
Wellcome Found |
Pharmacologically active compound
|
FR2741879A1
(fr)
*
|
1995-12-05 |
1997-06-06 |
Esteve Labor Dr |
Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
|
US6202491B1
(en)
|
1997-07-22 |
2001-03-20 |
Skf Condition Monitoring, Inc. |
Digital vibration coupling stud
|
GB9726987D0
(en)
|
1997-12-22 |
1998-02-18 |
Glaxo Group Ltd |
Compounds
|
US6124500A
(en)
*
|
1998-03-09 |
2000-09-26 |
Rohm And Haas Company |
Process for synthesizing benzoic acids
|
GB9812413D0
(en)
|
1998-06-10 |
1998-08-05 |
Glaxo Group Ltd |
Compound and its use
|
CA2334937C
(fr)
*
|
1998-12-14 |
2004-09-21 |
Torrent Pharmaceuticals Ltd. |
Procede et appareil ameliore de preparation de 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
|
US20020055177A1
(en)
*
|
1999-03-10 |
2002-05-09 |
Glaxo Wellcome Inc. |
Compound and its use
|
GB9907965D0
(en)
*
|
1999-04-09 |
1999-06-02 |
Glaxo Group Ltd |
Medical use
|
JP2002541215A
(ja)
*
|
1999-04-09 |
2002-12-03 |
ユーロ−セルティック エス. ア. |
ナトリウムチャネル遮断薬組成物およびその使用
|
AU763244B2
(en)
*
|
2000-01-03 |
2003-07-17 |
Rpg Life Sciences Limited |
A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
|
IL134730A
(en)
*
|
2000-02-25 |
2003-10-31 |
Chemagis Ltd |
Process for preparing substituted benzoyl cyanide amidinohydrazones
|
EE200300249A
(et)
|
2000-11-30 |
2003-10-15 |
Pfizer Products Inc. |
GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioon
|
EP1337271B1
(fr)
|
2000-11-30 |
2004-11-03 |
Pfizer Products Inc. |
Combinaison d'agonistes gaba et d'inhibiteurs de la sorbitol-deshydrogenase (sdi)
|
EP1390355A4
(fr)
*
|
2001-02-27 |
2005-02-23 |
Teva Pharma |
Nouvelles formes crystallines de la lamotrigine et procedes pour leur prepation
|
NZ531586A
(en)
*
|
2001-09-03 |
2005-09-30 |
Newron Pharm Spa |
Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use
|
CA2366521C
(fr)
|
2001-12-24 |
2007-03-06 |
Brantford Chemicals Inc. |
Un procede nouveau et efficace de preparation de lamotrigine et d'autres 3,5-diamino-1,2,4-triazines substituees en position 6
|
CN1649614A
(zh)
|
2002-02-22 |
2005-08-03 |
新河药品股份有限公司 |
活性剂传递系统和保护及施用活性剂的方法
|
ATE357217T1
(de)
*
|
2002-04-23 |
2007-04-15 |
Teva Pharma |
Pharmazeutische zusammensetzung enthaltend lamotrigine-partikel mit definierter morphologie
|
US8637512B2
(en)
|
2002-07-29 |
2014-01-28 |
Glaxo Group Limited |
Formulations and method of treatment
|
HU225667B1
(en)
|
2002-09-20 |
2007-05-29 |
Richter Gedeon Nyrt |
Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
|
ES2209639B1
(es)
|
2002-10-31 |
2005-08-01 |
Vita Cientifica, S.L. |
Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
|
EP1603889A1
(fr)
*
|
2003-03-17 |
2005-12-14 |
Hetero Drugs Limited |
Nouvelles formes cristallines de lamotrigine
|
WO2004085426A1
(fr)
|
2003-03-27 |
2004-10-07 |
Hetero Drugs Limited |
Nouvelles formes cristallines de candesartan cilexetil
|
BRPI0410271A
(pt)
|
2003-05-16 |
2006-05-16 |
Pfizer Prod Inc |
combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
|
WO2004103340A1
(fr)
*
|
2003-05-20 |
2004-12-02 |
Ranbaxy Laboratories Limited |
Comprimes hydrodispersibles a base de lamotrigine
|
GB2395483A
(en)
*
|
2003-07-03 |
2004-05-26 |
Jubilant Organosys Ltd |
Crystalline lamotrigine and its monohydrate
|
CA2548917C
(fr)
|
2003-12-11 |
2014-09-23 |
Sepracor Inc. |
Combinaison d'un sedatif et d'un modulateur des neurotransmetteurs, et methodes permettant d'ameliorer la qualite du sommeil et de traiter la depression
|
EP1737466A1
(fr)
*
|
2004-01-29 |
2007-01-03 |
Pfizer Products Inc. |
COMBINAISON DE MODULATEURS D'ACIDE GAMMA-AMINOBUTYRIQUE ET D'ANTAGONISTES DU RECEPTEUR 5-HT-1b
|
WO2005102366A2
(fr)
*
|
2004-04-19 |
2005-11-03 |
Philip Maxwell Satow |
Combinaisons de lithium et utilisations associees
|
PT1809271E
(pt)
*
|
2004-09-10 |
2010-08-30 |
Newron Pharm Spa |
Utilização de (halogenobenziloxi)benzilamino-propanamidas para o fabrico de medicamentos activos como moduladores selectivos dos canais de sódio e/ou de cálcio
|
US7825151B2
(en)
*
|
2005-09-23 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Hexahydro-cyclooctyl pyrazole cannabinoid modulators
|
US8378096B2
(en)
*
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
US8378117B2
(en)
*
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
RS51298B
(sr)
*
|
2005-09-23 |
2010-12-31 |
Janssen Pharmaceutica N.V. |
Modulatori heksahidro-ciklooktil pirazol kanabinoida
|
DK1937259T3
(da)
*
|
2005-09-23 |
2012-02-13 |
Janssen Pharmaceutica Nv |
Hexahydro-cycloheptapyrazol-cannabinoid-modulatorer
|
EP1937646A1
(fr)
|
2005-09-23 |
2008-07-02 |
Janssen Pharmaceutica N.V. |
Modulateurs cannabinoïdes de type tétrahydrocyclopentylpyrazole
|
US20070117858A1
(en)
*
|
2005-11-23 |
2007-05-24 |
Mingde Xia |
Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
|
US7526911B2
(en)
*
|
2006-02-03 |
2009-05-05 |
Rolls-Royce Corporation |
Gas turbine engine fuel system with fuel metering valve
|
WO2007095513A1
(fr)
*
|
2006-02-14 |
2007-08-23 |
Janssen Pharmaceutica, Nv |
Modulateurs cannabinoides de type tetrahydro-2h-indazole pyrazole
|
WO2007112402A1
(fr)
*
|
2006-03-27 |
2007-10-04 |
Janssen Pharmaceutica N.V. |
Modulateurs cannabinoïdes de type tétrahydro-1h-1,2,6-triazaazulènes
|
US20070254911A1
(en)
*
|
2006-03-27 |
2007-11-01 |
Mingde Xia |
Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
|
WO2007122638A2
(fr)
*
|
2006-04-26 |
2007-11-01 |
Ratnamani Bio-Chemicals & Pharmaceuticals Pvt. Ltd. |
Procede ameliore de preparation d'intermediaires de lamotrigine
|
DE602007003830D1
(de)
*
|
2006-05-31 |
2010-01-28 |
Calaire Chimie Sas |
Verfahren zur herstellung von lamotrigin und dessen zwischenprodukt 2,3-dichlorbenzoylchlorid
|
GB0613836D0
(en)
*
|
2006-07-13 |
2006-08-23 |
Univ Greenwich |
New medical use of triazine derivatives
|
US20120142919A1
(en)
|
2006-08-02 |
2012-06-07 |
Medichem, S.A. |
Method for synthesizing lamotrigine
|
CA2659290A1
(fr)
*
|
2006-08-14 |
2008-02-21 |
Jean-Paul Roduit |
Procede de preparation de lamotrigine
|
WO2008090114A1
(fr)
|
2007-01-24 |
2008-07-31 |
Glaxo Group Limited |
Compositions pharmaceutiques contenant du 2-méthoxy-5- (5-trifluorométhyl-tétrazol-i-yl-benzyl) - (2s-phényl-pipéridin-3s-yl-)
|
US7943653B2
(en)
*
|
2007-08-13 |
2011-05-17 |
Janssen Pharmaceutica N.V. |
Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
|
US20090076010A1
(en)
*
|
2007-09-13 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched lamotrigine
|
US8486927B2
(en)
*
|
2007-11-09 |
2013-07-16 |
Thar Pharmaceuticals |
Crystalline forms of lamotrigine
|
GB0800741D0
(en)
*
|
2008-01-16 |
2008-02-20 |
Univ Greenwich |
Cyclic triazo and diazo sodium channel blockers
|
US20100190752A1
(en)
*
|
2008-09-05 |
2010-07-29 |
Gruenenthal Gmbh |
Pharmaceutical Combination
|
MX2011012044A
(es)
|
2009-05-13 |
2011-12-14 |
Nektar Therapeutics |
Compuestos de triazina aromatica sustituida que contienen oligomeros.
|
US20100297195A1
(en)
|
2009-05-20 |
2010-11-25 |
Ranbaxy Laboratories Limited |
Controlled release lamotrigine formulations
|
GB2471729A
(en)
|
2009-07-08 |
2011-01-12 |
Univ Greenwich |
1,2,4-triazine derivatives and their use as sodium channel blockers
|
GB2471713A
(en)
|
2009-07-08 |
2011-01-12 |
Univ Greenwich |
1,2,4-triazine derivatives and their use as sodium channel blockers
|
US20110052686A1
(en)
|
2009-09-03 |
2011-03-03 |
Ranbaxy Laboratories Limited |
Modified release lamotrigine tablets
|
GB201111712D0
(en)
|
2011-07-08 |
2011-08-24 |
Gosforth Ct Holdings Pty Ltd |
Pharmaceutical compositions
|
WO2013183985A1
(fr)
|
2012-06-05 |
2013-12-12 |
Erasmus University Medical Center Rotterdam |
Procédé de traitement d'un trouble cognitif et composés pour l'utiliser
|
US10189859B2
(en)
|
2013-12-21 |
2019-01-29 |
Nektar Therapeutics |
Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
|
WO2016198878A1
(fr)
|
2015-06-12 |
2016-12-15 |
University Of Greenwich |
Dérivés de triazine en tant qu'inhibiteurs de l'interféron gamma
|
PT3554490T
(pt)
|
2016-12-16 |
2022-03-17 |
Idorsia Pharmaceuticals Ltd |
Combinação farmacêutica compreendendo um bloqueador de canais de cálcio de tipo t
|
TWI826531B
(zh)
|
2018-09-21 |
2023-12-21 |
南韓商愛思開生物製藥股份有限公司 |
具有㗁二唑之化合物及包含該化合物之醫藥組合物
|